Huang QX#, Qadri SF#, Bian H#, Yi XX, Lin CH, Yang XY, Zhu XP, Lin HD, Yan HM, Chang XX, Sun XY, Ma S, Wu Q, Zeng HL, Hu XQ, Zheng Y, Yki-Järvinen H, Gao X*, Tang HR*, Xia MF*. A metabolome-derived score predicts metabolic dysfunction- associated steatohepatitis and mortality from liver disease. J Hepatol 2025; 82: 781-793.

Xia MF#, Zeng HL#, Wang SJ, Tang HR*, Gao X*. Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR_based lipoprotein profiling. Journal of Hepatology 2021;74(4):974-977.

Li YF#, Xu JY#, Lu YT#, Bian H#, Yang L, Wu HH, Zhang XW, Zhang BL, Xiong MQ, Chang YF, Tang J, Yang F, Zhao L, Li J, Gao X, Xia MF*, Tan MJ*, Li JY*. DRAK2 aggravates nonalcoholic fatty liver disease  progression through SRSF6-associated RNA alternative splicing. Cell Metabolism. 2021; 33(10): 2004-2020.

Rong S#, Xia M#, Vale G, Wang S, Kim CW, Li S, McDonald JG, Radhakrishnan A, Horton JD. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER. Cell Metab 2024;36(3):617-629.

Xia MF#, Lin HD#, Chen LY, et al. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Diabetologia 2019;62:644-654.

Zhu XP#, Huang QX#, Ma S#, Chen LY, Wu Q, Wu L, Ma H, Li XM, Li Q, Aleteng Q, Hu Y, He WY, Gao J, Lin HD, Tang HR*, Gao X*, Xia MF*. Presence of sarcopenia identifies a special group of lean NAFLD in   middle-aged and older people. Hepatology International 2023;17:313-325.

Lin C#, Xia M#, Dai Y#, Huang Q, Sun Z, Zhang G, Luo R, Peng Q, Li J, Wang X, Lin H, Gao X, Tang H, Shen X, Wang S, Jin L*, Hao X*, Zheng Y*. Cross-ancestry analyses of Chinese and European populations reveal insights into the genetic architecture and disease implication of metabolites. Cell Genom. 2025;5(4):100810. 

Xia MF, Chen LY, Wu L, Ma H, Li XM, Li Q, Aleteng Q, Hu Y, He WY, Gao J, Lin HD*, Gao X*. Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study. Clin Nutr. 2021; 40(2):571-580.

Xia MF#, Rong SX#, Zhu XP, Yan HM, Chang XX, Sun XY, Zeng Hl, Li XM, Zhang LS, Chen LY, Wu L, Ma H, Hu Y, He WY, Gao J, Pan BS, Hu XQ, Lin HD*, Bian H*, Gao X*.Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J Bone Miner Res. 2021; 36:712-728.

Xia MF#*, Ma S#, Huang QX#, Zeng HL, Ge JY, Xu WJ, Wu Q, Wu L, Li XM, Ma H, Chen LY, Li Q, Aleteng Q, Hu Y, He WY, Pan BS, Lin HD, Zheng Y, Wang SJ, Tang HR*, Gao X*.NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study, Alimentary Pharmacology and Therapeutics 2022;55(6): 705-721.